Ein Arzt berät einen Patienten (Symbolbild).
Dienstag, 21.03.2023 05:45 von

IVVD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 3, 2023 in the Class Action Filed on Behalf of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Shareholders

Ein Arzt berät einen Patienten (Symbolbild). © TommL / Vetta / Getty Images https://www.gettyimages.de/

PR Newswire

NEW YORK, March 21, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ: IVVD) alleging that the Company violated federal securities laws.

This lawsuit is on behalf of all purchasers of Adagio common stock between November 29, 2021 and December 14, 2021, both dates inclusive.
Lead Plaintiff Deadline: April 3, 2023
No obligation or cost to you.

Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. NEWS - IVVD NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Invivyd you have until April 3, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Invivyd securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

Anzeige

Aktie im Fokus

Kurse

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the IVVD lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link: https://www.kleinstocklaw.com/pslra-1/invivyd-class-action-submission-form?id=37438&from=4.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
535 Fifth Avenue
4th Floor
New York City, NY 10017
jk@kleinstocklaw.com
Telephone: (212) 616-4899
www.kleinstocklaw.com

Cision View original content:https://www.prnewswire.com/news-releases/ivvd-alert-the-klein-law-firm-announces-a-lead-plaintiff-deadline-of-april-3-2023-in-the-class-action-filed-on-behalf-of-invivyd-inc-fka-adagio-therapeutics-inc-shareholders-301776813.html

SOURCE The Klein Law Firm

Werbung

Mehr Nachrichten zur Adagio Therapeutics Inc Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News

ARIVA.DE Redaktion Thumbnail
31.10.24 - ARIVA.DE Redaktion